Online citations, reference lists, and bibliographies.
← Back to Search

Efficacy Of Imatinib In Aggressive Fibromatosis: Results Of A Phase II Multicenter Sarcoma Alliance For Research Through Collaboration (SARC) Trial

R. Chugh, J. Wathen, S. Patel, R. Maki, P. Meyers, S. Schuetze, D. Priebat, D. Thomas, J. Jacobson, B. Samuels, R. Benjamin, L. Baker
Published 2010 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Purpose: Aggressive fibromatoses (AF; desmoid tumors) are rare clonal neoplastic proliferations of connective tissues that can be locally aggressive despite wide surgical resection and/or radiation therapy. The Sarcoma Alliance for Research through Collaboration (SARC) initiated a prospective phase II trial to investigate the outcome of patients treated with imatinib, a multiple tyrosine kinase inhibitor, in patients with AF, or 1 of 10 sarcoma subtypes. Here, we report specifically on the outcome of patients with AF as well as evaluations undertaken to examine the mechanism of imatinib. Experimental Design: Patients ≥10 years old with desmoid tumors that were not curable by surgical management or in whom curative surgery would lead to undesirable functional impairment were eligible. Imatinib was prescribed at 300 mg twice daily [body surface area (BSA) ≥ 1.5 m2], 200 mg twice daily (BSA = 1.0-1.49 m2), or 100 mg twice daily (BSA < 1.0 m2). Response outcomes at 2 and 4 months were assessed. Tissue specimens were analyzed by immunohistochemistry for expression of cKIT, platelet-derived growth factor receptor α (PDGFRα), PDGFRβ, AKT, PTEN, FKHR, and β-catenin. Tumor DNA was analyzed for PDGFRα exon 18 and APC mutations by allelic discrimination PCR. Results: Fifty-one patients were enrolled. The median number of prior regimens was 1. Kaplan-Meier estimates of 2- and 4-month progression-free survival rates were 94% and 88%, respectively, and 1-year progression-free survival was 66%. Objective response rate was 6% (3 of 51). Expression and polymorphisms of target proteins were identified in tissue samples, but no significant correlation with outcome was observed using the samples available. Conclusion: Imatinib may have a role in the management of unresectable or difficult to resect desmoid tumors. Clin Cancer Res; 16(19); 4884–91. ©2010 AACR.
This paper references
10.1002/SIM.1399
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.
P. Thall (2003)
Combination chemotherapy in ult desmoid tumors
WS Ferguson (1993)
10.1002/AJMG.1320280217
Occurrence of desmoids in patients with familial adenomatous polyposis of the colon.
S. Klemmer (1987)
10.1136/gut.2004.042705
Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation
N. J. Sturt (2004)
Noncytotoxic drug thery for intra - abdominal desmoid tumor in patients with familial adematous polyposis
K ukada (1992)
10.1097/00006534-198511000-00104
Radiation therapy in the treatment of aggressive fibromatoses (desmoid tumors).
K. D. Kiel (1984)
Updated outcome with long term low-up of imatinib for the treatment of progressive or recurrent gressive fibromatosis (desmoid tumor)
N Penel (2010)
Primary versus radiationociated craniofacial osteosarcoma : biologic and clinicopathologic parisons
JB Hugh (2006)
10.2106/00004623-198466090-00007
Extra-abdominal desmoid tumors.
M. G. Rock (1984)
10.1002/1097-0142(19931201)72:11<3244::AID-CNCR2820721118>3.0.CO;2-D
Combination chemotherapy in adult desmoid tumors
S. Patel (1993)
10.1016/j.ejca.2009.08.016
Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.
A. Constantinidou (2009)
10.1038/modpathol.3800334
Multiple gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study
R. Yantiss (2005)
10.1016/S0360-3016(97)00845-6
Individualizing management of aggressive fibromatoses.
M. Spear (1998)
Genetic nges of Wnt pathway genes are common events in metaplastic cinomas of the breast
D Thomas (2008)
Desmoid tumors and mesennt of aggressive fibromatoses
DJ Pritchard
Vinblastine and thotrexate for desmoid fibromatosis in children : results of a diatric Oncology Group Phase II Trial
K ukada (2007)
ltiple gastrointestinal stromal tumors in type I neurofibromais : a pathologic and molecular study
RK ntiss (2005)
The management of desmoid ors
JC ker (2010)
10.1002/cncr.20416
High‐dose tamoxifen and sulindac as first‐line treatment for desmoid tumors
N. Sturt (2004)
10.1200/JCO.2005.04.0717
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
M. Heinrich (2006)
10.1016/S1470-2045(09)70167-6
Gardner's syndrome (familial adenomatous polyposis): a cilia-related disorder.
E. G. Gómez García (2009)
Management of desmoid tumors.
J. G. Mckinnon (1989)
10.1046/J.1365-2168.1999.01222.X
Desmoid tumours complicating familial adenomatous polyposis
S. Clark (1999)
10.1200/JCO.2006.10.5015
Optimizing treatment of desmoid tumors.
D. Lev (2007)
10.1200/JCO.2003.05.150
Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution.
A. Gronchi (2003)
Successful chemotherapeutic dality of doxorubicin plus dacarbazine for the treatment of desid tumors in association with familial adenomatous polyposis
H Yanagi (2006)
Phase II multicenter trial of tinib in 10 histologic subtypes of sarcoma using a Bayesian hierhical statistical model
JK Wathen (2009)
Vinblastine and thotrexate for desmoid fibromatosis in children : results of a diatric Oncology Group Phase II Trial
WS Ferguson (2007)
10.1158/1078-0432.CCR-07-4379
Genetic Changes of Wnt Pathway Genes Are Common Events in Metaplastic Carcinomas of the Breast
M. Hayes (2008)
Radiation therapy in the treatment of aggressive romatoses ( desmoid tumors )
CG Morris (1984)
Desmoid tumours mplicating familial adenomatous polyposis
EB mezGarcia (1999)
10.1200/jco.2009.27.15_suppl.10518
Updated outcome with long-term follow-up of imatinib for the treatment of progressive or recurrent aggressive fibromatosis (desmoid tumor): A FNCLCC/ French Sarcoma Group phase II trial.
A. Dufresne (2009)
Clinical and molecular dies of the effect of imatinib on advanced aggressive fibromatosis smoid tumor )
A zarelli (2006)
Gardner ' s syndrome ( familial adenomas polyposis ) : a ciliarelateddisorder
EW ylor (2009)
Extra - dominal desmoid tumors
D Kotilingam (1984)
10.1002/1097-0142(20010901)92:5<1259::AID-CNCR1446>3.0.CO;2-Y
Low‐dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis
A. Azzarelli (2001)
10.1001/ARCHSURG.1979.01370340087015
Desmoid tumors and mesenteric fibromatosis in Gardner's syndrome: report of kindred 109.
E. W. Naylor (1979)
Combination chemotherapy in ult desmoid tumors
HL Evans (1993)
10.1200/JCO.2008.20.5054
Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.
R. Chugh (2009)
10.1200/JCO.2005.02.1923
Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis.
M. Gega (2006)
Radiation therapy in the treatment of aggressive romatoses ( desmoid tumors )
RA tecki (1984)
10.1002/cncr.11029
Response of extraabdominal desmoid tumors to therapy with imatinib mesylate
J. Mace (2002)
10.1111/j.1440-1746.2004.03542.x
Patterns of K‐ras codon 12 and 13 mutations found in pancreatic adenocarcinoma of 30 Chinese patients by microdissection, PCR and direct sequencing
S. Wei (2005)
10.1007/BF02053335
Noncytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis
K. Tsukada (1992)
10.1136/jcp.53.5.374
Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays
S. Wang (2000)
Clinical and molecular dies of the effect of imatinib on advanced aggressive fibromatosis smoid tumor )
GA McArthur (2006)
10.1002/cncr.22019
Primary versus radiation‐associated craniofacial osteosarcoma
J. Mchugh (2006)
10.3171/FOC.2007.22.6.22
Extraabdominal desmoid tumors.
Kurtus Dafford (2007)
The management of desmoid ors
JC (2002)
Successful chemotherapeutic dality of doxorubicin plus dacarbazine for the treatment of desid tumors in association with familial adenomatous polyposis
A nsmann (2006)
10.1200/JCO.2006.08.2966
Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial.
S. Skapek (2007)
Updated outcome with long term lowup of imatinib for the treatment of progressive or recurrent gressive fibromatosis ( desmoid tumor )
GA McArthur
10.1016/S0360-3016(02)02926-7
External beam radiotherapy for primary and adjuvant management of aggressive fibromatosis.
R. Zlotecki (2002)
Gardner ' s syndrome ( familial adenotous polyposis ) : a ciliarelated disorder
EW ylor (2009)



This paper is referenced by
10.1016/j.currproblcancer.2013.03.004
Emerging therapies for sarcoma.
S. Movva (2013)
10.21767/2471-8041.100042
Robotic-Assisted Distal Pancreatectomy for a Pancreatic Desmoid Tumor: A Case Report and Review of the Literature
G. Younan (2017)
10.1111/j.1365-2559.2012.04355.x
β‐Catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid‐type fibromatosis
Sebastian Huss (2013)
10.1186/1471-2407-14-870
The off-label use of targeted therapies in sarcomas: the OUTC’S program
L. Eberst (2014)
10.4321/S1130-01082012000300009
Multiple desmoid tumors in a patient with familial adenomatous polyposis caused by the novel W421X mutation.
O. Ioannidis (2012)
10.3941/jrcr.v6i3.897
Breast fibromatosis response to tamoxifen: dynamic MRI findings and review of the current treatment options.
M. Plaza (2012)
10.4236/OJPED.2013.34070
Desmoid tumor in a laparotomy scar in a child: Case report and brief literature review
J. Skondras (2013)
10.1016/j.mayocp.2017.02.012
Biology and Treatment of Aggressive Fibromatosis or Desmoid Tumor
K. Skubitz (2017)
10.3389/fonc.2019.00397
Activated Signaling Pathways and Targeted Therapies in Desmoid-Type Fibromatosis: A Literature Review
M. J. M. Timbergen (2019)
Desmoid-type fibromatosis in children. Clinical features, treatment response, and long-term follow-up
Daniela Fortunati (2020)
10.1586/era.12.180
Fibroblastic tumors of intermediate malignancy in childhood
A. Ferrari (2013)
10.1007/s11684-018-0672-6
Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects
Z. Wang (2019)
10.1016/j.ejca.2017.02.001
Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).
B. Kasper (2017)
Clinical question:What is the role for systemic therapy in advanced soft-tissue sarcoma?
(2019)
10.1016/S1470-2045(19)30323-7
The necessity for rigour in rare disease study design.
L. Baker (2019)
10.11138/RIO/2014.2.4.100
Overview in targeted therapy in advanced desmoid tumors
Amrallah A. Mohammed (2014)
Fibroma desmoplásico del hueso
Eliovigildo Meriño Martínez (2011)
10.3348/kjr.2017.18.1.94
Current Concepts in Non-Gastrointestinal Stromal Tumor Soft Tissue Sarcomas: A Primer for Radiologists
A. Baheti (2017)
10.1016/j.soc.2016.05.010
Desmoid-Type Fibromatosis: Evolving Treatment Standards.
M. Fiore (2016)
10.1016/j.crad.2015.04.015
Desmoid-type fibromatosis.
S. Otero (2015)
10.1016/J.REHAH.2015.06.004
Lesiones ocupantes de espacio no herniarias de la pared abdominal desde el prisma del oncólogo médico. El reto del abordaje de los tumores raros en la oncología del siglo xxi
V. Guillém (2015)
10.3889/mjms.1857-5773.2012.0262
Aggressive Fibromatosis Treatment - Imatinib Challenges
Gordana Damjanovska (2012)
10.1002/cncr.32120
Autophagy inhibition overcomes sorafenib resistance in S45F‐mutated desmoid tumors
D. Braggio (2019)
10.1186/s13569-016-0060-4
UK guidelines for the management of soft tissue sarcomas
A. Dangoor (2016)
10.1016/S1470-2045(19)30276-1
Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.
M. Toulmonde (2019)
10.2147/CMAR.S23257
New drugs and combinations for the treatment of soft-tissue sarcoma: a review
N. Somaiah (2012)
10.1016/J.AFORL.2016.04.005
Tumeurs desmoïdes cervico-faciales de l’enfant : mise au point sur la prise en charge
M. Risoud (2017)
10.2995/JACSURG.25.672
A case of locally recurrent chest wall desmoid tumor effectively treated with radiotherapy
T. Hasumi (2011)
10.1111/cas.14528
Risk factors of local recurrence after surgery in extraabdominal desmoid‐type fibromatosis: A multicenter study in Japan
Y. Nishida (2020)
10.1056/NEJMoa1805052
Sorafenib for Advanced and Refractory Desmoid Tumors
M. Gounder (2018)
10.1007/s00432-020-03498-y
Efficacy and safety of apatinib for patients with advanced extremity desmoid fibromatosis: a retrospective study
Chuanxi Zheng (2021)
10.1002/hed.23092
Aggressive fibromatosis in the head and neck region: Benign tumor with often mutilating effects
Mathijs P. Hendriks (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar